StellarGene Technologies is a company driven by Science and its applicability in Healthcare and Agriculture. We work in conjunction with Scientists, Clinicians and the Community bringing Genomic solutions to Research, Medicine and Lifestyle.
Lead by a Highly Experienced Team motivated by the Potential of Genomics, we carry the vision of offering
• Diagnostics that enable Decisions • Planning that leads to Publications • Trainings that lead to empowerment
We engage the latest technologies including Microarray and Next Generation Sequencing to deliver
• Quality • Insights • Actionability • Promptness • Growth
Analyse the entire Genome – Accurately detect numerous chromosomal variations at higher resolution than karyotyping
and more comprehensively than conventional FISH. Provide High specificity, sensitivity, accuracy, and resolution across
Detect Multiple Aberrations – CMA can accurately detect numerous chromosomal variations of different types, sizes, and genomic locations. In addition to identifying copy number changes- Deletions, Duplications, CMA is capable of detecting allelic imbalances and copy number neutral abnormalities such as AOH/LOH that can be associated with uniparental disomy (UPD) or consanguinity, both of which may pose increased risk for autosomal recessive conditions.
Acceptance - The American Academy of Neurology (AAN), the American College of Medical Genetics (ACMG), the American College of Obstetricians and Gynaecologists (ACOG) and the International Collaboration for Clinical Genomics (ICCG/ISCA) recommend chromosomal microarray analysis (CMA) as the first-line test to aid in the diagnostic evaluation of intellectual disability.